coteau Get App
PRME

PRME

Prime Medicine, Inc.
$3.92
+2.35% 2026-10-20
Healthcare
1M3M6M1Y2Y
-56%-38%-20%-1%+17%Oct 2025Apr 2026Oct 2026
PRMESPY
1W
+18.1%
1M
+25.6%
3M
+25.6%
6M
+2.9%
YTD
+13.0%
1Y
-36.6%

Live chart

Loading live chart…

Grades vs sector

Momentum
Not enough data yet
–

Percentile within its GICS sector across the S&P 1500.
Growth
Not enough data yet
–

Percentile within its GICS sector across the S&P 1500.
Value
Not enough data yet
–

Percentile within its GICS sector across the S&P 1500.
Profitability
Not enough data yet
–

Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–

30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 5 live models right now.

Quality Growth
not ranked (outside this model's universe or screens)
 Momentum Top 15
not ranked (outside this model's universe or screens)
 Momentum Blend
not in the current book
 New Highs Growth
not ranked (outside this model's universe or screens)
 Conviction 20
not in the current book

News

More news
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
Zacks · Oct 12
Canadian Investment Regulatory Organization Trade Resumption - PRME
CNW Group · Oct 05
Prime Medicine Doses First Patient in Trial of Investigational Wilson Disease Treatment
MT Newswires · Oct 05
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
GlobeNewswire · Oct 05
Canadian Investment Regulatory Organization Trading Halt - PRME
CNW Group · Sep 30

Key stats

Market cap$711.0M
P/E (trailing)–
P/E (forward)-4.4
52-week range2.67 – 6.30
Revenue growth (YoY, latest qtr)+3.5%
Dividend yield0.00%
Analyst consensusStrong Buy (11)
Mean price target$7.11 (+81%)
Valuation and fundamentals

Valuation & fundamentals

Bottom line
No cash-flow valuation
Model read-out from the numbers below, not advice. Score +0 (DCF counts double).
•Piotroski F-score4/9
▼Altman Z-5.7 (distress)
▲Analyst target+81% (11 analysts)

Discounted cash flow

Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.
Reverse DCFfor context, not a signal
Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.
Edit assumptions · recalculates instantly
Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (FY to 2025-12-31). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 2.38 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs sector

Forward EPS $-0.89 vs trailing $-1.07. Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin
–
Operating margin
-4242.7%
FCF margin
-3386.2%
Net margin
-4056.4%
Return on equity
-472.0%
Return on invested capital
–
Net debt / EBITDA
–
Current ratio
3.1×
Interest cover
–
Cash conversion (OCF/NI)
–
Piotroski F-score 4/9 · last two fiscal years
✗ Positive net income✗ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved

Altman Z-score -5.7 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target
$7
+81%
Analysts
11
Strong Buy
Range
$4–$11
low – high
● price · ◆ mean target

Annual history

FYRevenueNet incomeFree cash flow
2025$4.6M$-201.1M$-167.1M
2024$3.0M$-195.9M$-130.2M
2023$0$-198.1M$-174.1M
2022$0$-121.8M$-147.9M
2021$0$-165.4M$-38.2M
2020$5.2M$-3.4M$-6.2M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR –.

Earnings

Next report: 2026-11-06 · before open · EPS est -0.23
24-1125-0225-0525-0825-1126-0326-0526-08-0.440.00
EstimateActual (beat)Actual (miss)
ReportEPS estActualSurprise
2026-08-06-0.26-0.24+6.0%
2026-05-07-0.25-0.28-12.6%
2026-03-03-0.26-0.24+6.9%
2025-11-07-0.25-0.32-29.4%
2025-08-07-0.34-0.41-20.6%
2025-05-08-0.31-0.40-28.0%
2025-02-28-0.31-0.31+0.4%
2024-11-12-0.42-0.44-4.7%

Quarterly revenue

QuarterRevenueYoY
2026-06-30$1.2M+3.5%
2026-03-31$856.0K–
2025-12-31$838.0K–
2025-09-30$1.2M–
2025-06-30$1.1M–
Analyst actions
Chardan Capital
2026-09-25 · main
Buy → Buy
PT $7
Chardan Capital
2026-08-25 · main
Buy → Buy
PT $7
BMO Capital
2026-08-19 · init
Outperform → Outperform
PT $9
HC Wainwright & Co.
2026-08-10 · reit
Buy → Buy
PT $8
HC Wainwright & Co.
2026-06-29 · up
Neutral → Buy
PT $8
Oppenheimer
2026-03-12 · init
 → Outperform
PT $11

Stats refreshed 2026-10-20 18:13:47 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

coteau

Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.

How it worksDisclaimerTermsPrivacyData status